{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.38","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3201","pValueComment":"Two-sided significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"1.75","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"13.4","value":"5.3"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"17.0","value":"10.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"description":"Failure is defined as Death from second primary, protocol treatment, or \"other cause\". Failure time is defined as time from randomization to first occurrence of failure, death due to study cancer or unknown cause (competing risk), or last follow-up (censored). Failure rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year estimates are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\\^2 IV starts one week prior to RT, then 250 mg/m\\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"RT+ Cetuximab"},{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"RT + Durvalumab"}],"paramType":"NUMBER","populationDescription":"Randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years.","title":"Competing Mortality (Percentage of Participants Who Died Due to Causes Other Than Study Cancer)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}